Needham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD)

Amicus Therapeutics (NASDAQ:FOLD)‘s stock had its “hold” rating restated by equities researchers at Needham & Company LLC in a report issued on Thursday,Benzinga reports.

A number of other research analysts also recently commented on the stock. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. StockNews.com downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Guggenheim lifted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Amicus Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $16.88.

Amicus Therapeutics Stock Performance

Shares of Amicus Therapeutics stock opened at $9.56 on Thursday. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -28.12, a price-to-earnings-growth ratio of 1.65 and a beta of 0.61. The stock’s 50-day moving average is $9.58 and its 200-day moving average is $10.42. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics has a one year low of $8.78 and a one year high of $14.02.

Insider Activity at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $8,884,273.08. This represents a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.20% of the stock is currently owned by insiders.

Institutional Trading of Amicus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. OLD Second National Bank of Aurora bought a new stake in Amicus Therapeutics in the 3rd quarter worth about $26,000. Hazlett Burt & Watson Inc. increased its holdings in Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,569 shares in the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Amicus Therapeutics in the fourth quarter worth $29,000. Blue Trust Inc. raised its holdings in Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,831 shares during the period. Finally, Arcadia Investment Management Corp MI purchased a new position in Amicus Therapeutics in the 3rd quarter worth approximately $32,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.